You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

353 Results
Drug
Other Name(s): Reblozyl®
Updated
Sep 2025
Drug
Other Name(s): Blincyto®
Updated
Sep 2025
Drug
Other Name(s): Camptosar®
Updated
Sep 2025
Drug
Other Name(s): Imbruvica®
Updated
Sep 2025
Drug
Other Name(s): Neulasta®, Lapelga®, Fulphila™; Ziextenzo®; Nyvepria™, Niopeg®, Pexegra™
Updated
Sep 2025
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®, Filra™
Updated
Sep 2025
Drug
Other Name(s): Femara®
Updated
Sep 2025
Drug
Other Name(s): Tykerb®
Updated
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Palliative
Funding:
New Drug Funding Program
    Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)
New Drug Funding Program
    Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph- BCP-ALL)
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
New Drug Funding Program
    Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Sep 2025
Drug
Other Name(s): Elrexfio™
Updated
Sep 2025

Pages